Sanofi mulls insulin production in India amid rising emerging markets focus
This article was originally published in Scrip
Sanofi is weighing plans to manufacture insulin in India, a move that is perhaps indicative of a significant strategic shift underway at the French giant as it gears to build on its diabetes franchise in emerging markets, where bulk of the disease is and will be concentrated.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.